Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656577 · ClinicalTrials.gov registry record · Early Phase 1
Pexacerfont for Stress-induced Food Craving
A Early Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT01656577: Clinical Trial Early Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01656577 is a Early Phase 1 study that was terminated before completion, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 31 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01656577, a Early Phase 1 study, was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Background: \- Stress can cause people to give in to temptations to eat less healthily. People who are on weight loss diets often have problems sticking to their diets when they are stressed. Some tests have shown that the drug pexacerfont can help reduce stress-related seeking of high-calorie foods. However, it has not been tested on reducing food craving. Researchers want to test pexacerfont on people who are on diets to see if it can reduce stress-related food cravings. Objectives: \- To see if pexacerfont can help reduce stress-induced food cravings. Eligibility: \- Individuals between 21 and 65 years of age who are on a diet to control their weight. Design: * Participants will be screened with a physical exam and medical history. This study requires seven visits over about 35 days. * Participants will take either pexacerfont or placebo pills during the study. They will have three pills every morning. They will record video of themselves taking the pills every day. * Every evening, participants will fill out a questionnaire. It will ask questions about feelings and behaviors related to eating and food craving. * Participants will have regular study visits while taking the pills. The visits will involve questions about stressful situations and food cravings. One visit will involve a mildly stressful math test, followed by tasting of different foods. This test will look at whether pexacerfont can affect food preferences. Participants will provide blood and saliva samples as directed at these study visits. * Participants will have follow-up phone calls 1, 3, and 6 months after the end of the study.
Interventions
- DRUG Pexacerfont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-09 |
| Phase | Early Phase 1 |
Why NCT01656577 stopped before completion
NCT01656577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which Pexacerfont is the first listed.
NCT01656577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01656577 about?
NCT01656577 is a clinical study titled "Pexacerfont for Stress-induced Food Craving". Background: \- Stress can cause people to give in to temptations to eat less healthily. People who are on weight loss diets often have problems sticking to their diets when they are stressed. Some tests have shown that the drug pexacerfont can help reduce stress-related seeking of high-calorie food...
What is the current status of trial NCT01656577?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2012-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01656577?
The interventions under investigation include: Pexacerfont (DRUG).
Who is sponsoring clinical trial NCT01656577?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01656577's enrollment target sits among peer trials
31 794th of 2000 higher than 1,194 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia